Эффективность и пути оптимизации лечения острого лимфобластного лейкоза у детей
Диссертация
Установлено, что использование системы стратификации модифицированного протокола А1Х-ВРМ-95т приводит к перераспределению детей группы высокого риска в группы стандартного и среднего риска и увеличению количества рецидивов у детей средней группы риска. Использование системы стратификации модифицированных протоколов А1Х-ВЕМ-90т и АЬЬ-ВРМ-95т без проведения цитогенетических и молекулярно… Читать ещё >
Содержание
- Глава I. Основы современной терапии острого лимфобластного лейкоза у детей (обзор литературы)
- 1. 1. Факторы прогноза у детей с острым лимфобластным лейкозом
- 1. 2. Классификации групп риска у детей с острым лимфобластным лейкозом
- 1. 3. Программная химиотерапия острого лимфобластного лейкоза у детей
- Глава II. Клинические данные и методы исследования
- 2. 1. Характеристика пациентов
- 2. 2. Диагностика и определение событий
- 2. 3. Краткое описание модифицированных протоколов А1Х-ВРМ-90т и А1Х-ВРМ-95т
- 2. 4. Критерии анализа результатов клинических исследований
- 2. 5. Статистический анализ
- Глава III. Клинические и параклинические данные у детей с острым лимфобластным лейкозом в первом остром периоде
- Глава 1. У. Результаты лечения детей с острым лимфобластным лейкозом по модифицированным протоколам АЬЬ-ВРМ-90т и А1Х-ВРМ-95т
- 4. 1. Общие результаты лечения детей с острым лимфобластным лейкозом по модифицированным протоколам А1Х-ВРМ-90т и АЬЬ-ВРМ-95т
- 4. 2. Результаты лечения детей с острым лимфобластным лейкозом группы стандартного риска по модифицированным протоколам АЬЬ-ВРМ-90ш и А1Х-ВРМ-95т
- 4. 3. Результаты лечения детей с острым лимфобластным лейкозом группы среднего риска по модифицированным протоколам А1Х-ВРМ-90т и А1Х-ВРМ-95т
- 4. 4. Результаты лечения детей с острым лимфоблстным лейкозом группы высокого риска по модифицированным протоколам ALL-BFM-90m и ALL-BFM-95m
- 4. 5. Эффективность средних доз метотрексата в профилактике рецидивов с вовлечением центральной нервной системы и testis у детей с острым лимфобластным лейкозом
- Глава. Y. Анализ токсичности терапии острого лимфобластного лейкоза у детей по протоколам ALL-BFM-90m и ALL-BFM-95m
- 5. 1. Гематологическая токсичность
- 5. 2. Инфекционные осложнения
- 5. 3. Анализ продолжительности интенсивной фазы протоколов ALL-BFM
- 90. т и ALL-BFM-95m. Эпизоды редукции терапии
- Глава. YI. Прогностическое значение клинико-лабораторных данных у детей с острым лимфобластным лейкозом
- Глава. YII. Результаты лечения и пути оптимизации терапии острого лимфобластного лейкоза у детей (обсуждение полученных данных)
- Выводы
Список литературы
- Алейникова О.В. Результаты лечения острого лимфобластного лейкоза у детей Беларуси // Гематология и трансфузиология. 1997. — № 5. — С. 18−21.
- Байдун J1.B., Романенкова И. А., Ппясунова С. А., М ад заев С. Р. Развёрнутая иммунофенотипическая характеристика CD 10+ острого лимфобластного лейкоза B-линии у детей // Гематология и тг? нсфузиология.- 1998.- т. 43.- N 6.-С. 13−16.
- Беликова Л.Ю. Сравнительная эффективность и токсичность терапии острого лимфобластного лейкоза у детей по протоколам ALL-REZ BFM в Берлине и в Москве. Автореферат дисс. канд. мед. наук, М., 1999, 38 с.
- Гаврикова Н.В. Клинико-иммунологическая характеристика ствол о во клеточного подварианта острого лимфобластного лейкоза у детей. Автореферат дисс. канд. мед. наук, М., 2000, 24 с.
- Г. В. Коленкова, Р. В. Ленская, Н. С. Кисляк. Результаты моноклонального иммунофенотипирования лейкозных клеток костного мозга у 169 детей с острым лейкозом // Гематология и трансфузиология.- 1997.- т. 42.- N 5.- С. 25−28.
- Карачунский А.И. Стратегия терапии острого лимфобластного лейкоза у детей. // Дисс. докт. мед. наук.- М 1999. — С. 53.
- Кошель И.В. Клинико патогенетическая оценка ремиссий острого лейкоза у детей. // Дисс. докт. мед. наук.- M — 1971.
- Курдюков Б.В. Прогностическое значение клинико-иммунологической характеристики острого лимфобластного лейкоза у детей. Автореферат дисс. канд. мед. наук, М., 1997, 23 с.
- Мадзаев С.Р. Значение дифференцировочных антигенов бластных клеток в клинике и прогнозе острого лимфобластного лейкоза у детей. Автореферат дисс. канд. мед. наук, М., 2000, 25 с.
- Р.Ф. Тепаев, О. А. Полякова, А. А. Басистова и др. Результаты лечения острого лимфобластного лейкоза у детей по модифицированным протоколам ALL-BFM-90m и ALL-BFM-95m // Гематология и трансфузиология.- 2002.- Т. 47.- № 4.- С. 11−14.
- A. Biondi, G. Cimino, R. Pieters, C.H. Pui Biological and therapeutic aspects of infant leukemia // Blood.- 2000.- V. 96.- N. 1.- P. 24−33.
- Appelbaum F.R. Allogeneic hematopoietic stem cell transplantation for acute leukemia // Semin Oncol.- 1997.- Vol. 24.- P. 114−123.
- Arico M., Basso G., Mandelli F. et al. Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia // Cancer.- 1995.- Vol. 75.- P. 1684−1693.
- Arico M., Valsecchi M.G., Camitta B. et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia // New England Journal of Medicine.- 2000.- Vol. 342.- P. 998−1006.
- Asselin B., Gelber R., Saltan S. Relative toxicity of E. Coli (-asparaginase (ASP) and PEG asparaginase (PEG) in newly diagnosed childhood acute lymphoblastic leukemia (ALL) // Medical and Pediatric Oncology.- 1993.- Vol. 21.- p. 556.
- Barredo J.C., Synold T.W., Laver J. et al. Differences in constitutive and post-methotrexate folypoyglutamate synthetase activity in B-lineage and T-lineage leukemia // Blood.- 1994.- Vol. 84.- P. 564−569.
- Basso G., Putti M.C., Cantu-Rajnoldi A. et al. The immunophenotype in infant acute lymphoblastic leukaemia: correlation with clinical outcome. An Italian multicentre study (AIEOP) // Britisch Journal of Haematology.- 1992.- Vol. 81.-P. 184−191.
- Behm F.G., Rimondi S.C., Frestedt J.L. et al. Rearrangment of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukaemia, regardless of presenting age // Blood.- 1996.- Vol. 87.- P. 2870−2877.
- Bene M.C., Castoldi G., Knap W. et al. Proposals for the immunological classification of acute leukaemias // Leukemia.- 1995.- Vol. 9.- P. 1783−1786.
- Bennet J.M., Catovsky D., Daniel M.T. et al. Proposals for the classification of the classification of the acute leukaemias // British Journal of Haematology.-1976.- Vol. 33.- P. 451−458.
- Bennett J.M., Catovsky D., Daniel M.T. et al. The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations // British Journal of Haematology.- 1981.- Vol. 47.- P. 553−561.
- Berger R., Bernheim A. Cytogenetic studies on Burkitt’s lymphoma-leukemia // Cancer Genetics and Cytogenetics.- 1982.- Vol. 7.- P. 231−244.
- Bernard O.A., Berger R. Molecular basis of 11 q23 rearrangements in hematopoietic malignant proliferations // Genes, Chromosomes and Cancer.1995.-Vol. 13.-P. 75−85.
- Beyrmann B., Adams H.P., Henze G. et al. Philadelphia chromosome in relapsed childhood acute lymphoblastic leukemia- A matched-pair Analysis // Journal of Clinical Oncology.- 1997.- Vol. 15.- N 6.- P. 2231−2237.
- Birch J.M. Epidemiology of paediatric cancer. In: Duncan W. (ed) Paediatric oncology. Springer, Berlin Heidelberg, New York, Tokyo. 1983. — P. 1−10.
- Bleyer W.A. Neurologic sequelae of methotrexate and ionizing radiation: a new classification // Cancer Treat Rep.- 1981.- Vol. 65.- P. 89−98.
- Boos J., Jurgens H. Pegaspargase (polyethylene glycol-l-asparaginase) a viewpoint by Joachim Boos and Herbert Jurgens // Clinical Immunotherapeutics.1996.- Vol. 5.- P. 497−498.
- Boos J., Weber G., Ahlke E. et al. Monitoring of asparaginase activity asparaginase levels in children on different asparaginase preparations // European Journal of Cancer.- 1996.- Vol. 32a.- P. 1544−1550.
- Borkhardt A., Cazzaniga G., Viehmann S. et al. Incidence and clinical relevance of TEL/ ML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials // Blood.-1997.- Vol. 90.- P. 571−577.
- Borsi J.D., Moe P.J. A comparative study on the pharmacokinetics of methotrexate in a dose range of 0,5 g to 33r6 g/m2 in children with acute lymphoblastic leukaemia//Cancer.- 1987.- Vol. 60.- P. 5−13.
- Bostrom B., Gaynon P., Sather H. et al. Dexamethasone (DEX) decreases central nervous system (CNS) relapse and improves event-free survival (EFS) in lower risk acute lymphoblastic leukemia (ALL) // Proc Am Soc Clin Oncol.- 1998.-Vol. 17.- P. 527a.
- Brisco M.J., Condon J., Hughes E. Et al. Outcome prediction in childhood acute lymphoblastic leukemia by molecular quantitation of minimal residual disease at the end of induction // Lancet.- 1994.- Vol. 343.- P. 196−200.
- Brisco M.J., Sykes P.J., Hughes E. et al. Monitoring minimal residual desease in peripheral blood in B-lineage ALL // British Journal of Haematology.- 1997.-Vol. 99.- P. 314−319.
- Buhrer C., Henze G., Hofmann J. et al. Central nervous system relapse prevention in 1165 standard-risk children with acute lymphoblastic leukemia in five Bfm trials // Hamatol Bluttransfus.- 1990.- Vol. 33.- P. 500−503.
- Campana D., Coustan-Smith E. Detection of minimal residual desease in acute leukemia by flow cytometry // Cytometry.- 1999.- Vol. 15.- P. 139−152.
- Cave H., van der Werff ten Bosch J., Suciu S. et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia // Neu England Journal of Mrdicine.- 1998.- Vol. 339.- P. 591−598.
- Chessells J.M., Bailey C., Richards S.M. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALLX // Lancet.- 1995.- Vol. 345.- P. 143−148.
- Chessells J.M., Eden O.B., Bailey C.C. et al. Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL trials report from the Medical Research Council Working Party on Childhood Leukaemia // Leukemia.- 1994.- Vol. 8.- P. 1275−1279.
- Chessels J.M., Hall E., Prentice H.G., et al. The impact of age on outcome in lymphoblastic leukaemia: MRC UKALL X and XA compared: a report frome the MRC Paediatric and Adult Working Parties // Leukaemia.- 1998.- Vol. 12.- P. 463−473.
- Chessels J.M., Richards S.M., Bailey C.C. et al. Sex and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKA11 TRIALS // British Journal of Haemotology.- 1995.- Vol. 89.- P. 372−380.
- Cheung Y.F., Lee C.W., Chan C.F. et al. Somatostatin therapy in l-asparaginase-induced pancreatitis // Medical and Pediatric Oncology.- 1994, — Vol. 22.- P. 421 424.
- Childhood ALL Collaborative Group. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children // Lancet.- 1996.- Vol. 347.- P. 1783−1788.
- Ching-Hon Pui, William E. Evans. Acute Lymphoblastic Leukemia // The New England Journal of Medicine.- 1998.- Vol. 339.- N 9.- P. 605−615.
- C.H. Pui, S. Salan, M.V. Relling et al. International childhood Acute Lymphoblastic Leukemia workshop: Sausalito, CA, 30 November-1 December 2000 // Leukemia.- 2001.- Vol. 15.- P. 707−715.
- Christine J. Harrison. The genetics of childhood acute lymphoblastic leukemia // Bailliere’s Clinical Haematology.- 2000.- Vol. 13.- N 3.- P. 427−439.
- Chessells J.M., Bailey C., Richards S.M. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UK LL X // Lancet.- 1995.- Vol. 345.- P. 143−8.
- Chessells J.M., Harriso G., Lilleyma J.S. et al. Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UK LL X // British Journal of Haematology.- 1997.- Vol. 98.- P. 945−951.
- Christi W.M., Carrol A.J., Shuster J.J. et al. Poor prognosis of children with pre-B acute lymphoblastic leukaemia is associated with the t (l-19Xq23−13): Paediatric Oncology Group study // Blood.- 1990.- Vol. 76.- P. 117−122.
- Conter V., Schrappe M., Arico M. et al. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone // Journal of Clinical Oncology.- 1997.- Vol. 15.- P. 2786−2791.
- Cortes J.E., Kataijia H.M. Acute lymphoblastic leukemia: ^ comprehesive review with emphasis of biology and therapy // Cancer.- 1995.- Vol. 76.- P. 2393−417.
- Coustan-Smith E., Behm F.G., Sanchez J. et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukemia // Lancet.- 1998.- Vol. 351.- P. 550−554.
- C. Patte. B-acute lymphoblastic leukemia // International Journal of Pediatric Hematology/Oncology.- 1998.- Vol. 5.- P. 81−88.
- Cutter J., Mick R., Budma D.R. et al. Phase III trial of brief intensive treatment of adult acute lymphoblastic leukemia comparing daunorubicin and mitoxantrone: a CALGB study // Leukemia.-1991.- Vol. 5.- P. 425−31.
- D.O. Harms, G.E. Janka-Schaub. Co-operative study group for childhood acute lymphoblastic leukaemia (COALL): long-term follow-up of trials 82, 85, 89 and 92 // Leukemia.- 2000.- Vol. 14.- P. 2234−2239.
- Dordelmann M., Reiter A., Borkhardt A. et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia // Blood.- 1999,-Vol. 94.- P. 1209−1217.
- Dordelmann M., Schrappe M., Reiter A. et al. Downs syndrome in childhood acute lymphoblastic leukaemia: clinical characteristics and treatment outcome in four consecutive BFM trials // Leukemia.- 1998.- Vol. 12.- P. 645−651.
- Dreyer Z.E., Steuber C.P., Bowman W.P. et al. High risk infant ALL and improved survival with intensive chemotherapy // Proc Am Soc Clin Oncol.-1998.- Vol. 17.- p. 529a.
- Eckert C., Landt o., Taube T. et al. Potential of lightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia // Leukemia.- 2000.- Vol. 14.- P. 316−323.
- E. Forcsticr, B. Johansson, G. Gustafsson et al. Prognostic impact of karyotypic findings in childhood acute lymphoblastic leukemia: Nordic eries comparing two treatment periods // British Journal of Haemotology.- 2000.- Vol. 110.- P. 147 153.
- E.J. Estlin. Optimizing antimetabolite-based chemotherapy for the treatment of childhood acute lymphoblastic leukaemia / British Journal of Haematology.-2000.- Vol. 110.- P. 29−40.
- Elaine Coustan-Smith, Jose Sancho, Michael L. Hancock et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia // Blood.- 2000.- Vol. 96.- N 8.- P. 2691−2696.
- Evans W.E., Crom W., Abromowitch M. et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia // New England Journal of Medicine.- 1986.- Vol. 314.- P. 471−477.
- Evans W.E., Relling, M., Rodman, J.H. et al. Conventional compared with individualised chemotherapy for childhood acute lymphoblastic leukemia // New England Journal of Medicine.-1998.- Vol. 338.- P. 499−505.
- E. Vilmer, S. Suciu, A. Ferster et al. Long-term results of three randomized trials (58 831, 58 832, 58 881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report // Leukemia.- 2000.- Vol. 14.- P. 2257−2266.
- Piere D., Lepage E., Sebba C. et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy // Journal of Clinical Oncology.- 1993.- Vol. 11, — P. 19 902 001.
- Fink F.M., Roller U., Mayer H. et al. Prognostic significance of myeloid-associated antigen expression on blast cells in children with acute lymphoblastic leukemia // Medical Pediatric Oncology.- 1993.- Vol. 21.- P. 340−346.
- Forestier E., Gustafsson G., von Heideman A., A. Heim et al. Prognostic impact of bone marrow karyotype in childhood acute lymphoblastic leukaemia: Swedish experiences 1986−1991 //Acta Paediatrics.- 1997.- Vol. 86.- P. 819−825.
- Foroni L., Harrison C.J., Hoffbrand A.V., Potter M.N. Investigation of minimal residual diseas in chaldhood and adult acute lymphoblastic leukemia by molecular analysis // British Journal of Haemotology.- 1999.- Vol. 105.- P. 7−24.
- Frankel S.R., Kurtzberg J., De lei vera, D. et al. Toxicity and pharmacokinetics of PEG-asparaginase (PEG-asp) in newly diagnosed adult acute lymphoblastic leukemia (ALL): CALGB 9511 // Blood.- 1996.- Vol. 88 (Suppl. 1/1), 669a.
- Frankel L.S., Ochs J., Shuster J.J. et al. Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493) // Journal of Pediatric Hematology and Oncology.- 1997.-Vol. 19.- P. 35−42.
- Gajjar A., Ribeiro R., Hancock M.L. et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia // Blood.- 1995.- Vol. 86.- P. 1292−1295.
- Gaynon P. S., Desai A.A., Bostrom B.C. et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review // Cancer.- 1997.-V. 80.- P. 1717−1726.
- GFCH. Group Francais de Cytogenetique Hematologique: collaborative study of karyotypes in childhood acute lymphoblastic leukemia // Leukemia.- 1993.- Vol. 7.- P. 10−19.
- Goker E., Lin J.T., Trippet T. et al. Decreased polyglutamation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this desease//Leukemia.- 1993.- Vol. 7.- P. 1000−1004.
- Goulden N.J., Knechtli C.J.C., Garland R. et al. Minimal residual disease analysis for the prediction of relapse in children with standard risk acute lymphoblastic leukemia // British Journal of Haematology.- 1998.- Vol. 100.- P. 235−244.
- Griffin T.C., ShusterJ.J., Buchanan G.R. et al. Slow disappearance of peripheral blood blasts is an adverse prognostic factor in childhood T cell acute lymphoblastic leukemia: a Pediatric Oncology Group study // Leukemia.- 2000.-Vol. 14.- P. 792−795.
- Harrison C.J., Cuneo A., Clark R. et al. Ten novel llq23 chromosomal partner sites // Leukemia.- 1998.- Vol. 12.- P. 811−822.
- Heerema N.A., Nachmann J.B., Sather H.N. et al. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from CCG // Blood.- 1999.- Vol. 84.- P. 4036−4046.
- H.J. Muller, L. Loning, A. Horn et al. Pegylated asparaginase (OncasparTM) in children with ALL: drug monitoring in reinduction according to the ALL/NHL
- BFM 95 protocols // British Journal of Haematology.- 2000.- Vol. 110.- P. 379 384.
- Hoelzer D., Ludwig W., Eckhard E. et al. Improved outcome in adult B-cell acute lymphoblastic leukemia // Blood.-19%.- Vol. 87.- P. 495−508.
- H. Riehm. Therapieprotokoll All-BFM 95 / Hannover.- 1995.- p. 20.
- H. Riehm, H.J. Feickert. Therapy results in five ALL-BFM studies since 1970. Implications of risk factors for prognosis // Haematology and Blood Transfusions.- Vol. 30.- N 139.- P. 51.
- H. Riehm, H. Gadner, G. Henze et al. Acute lymphoblastic leukemia: treatment in three BFM studies (1970−1981). In Murphy S.B., Gilbert J.R. / Editors, Leukemia Research: advances in cell biology and treatment. Elsevier, Amsterdam, 1983, P. 251−263.
- Hurwitz C.A., Silverman L.B., Schorin M.A. et al. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia // Cancer.- 2000.- Vol. 88.- P. 1964−1969.
- Ito C., Evans W.E., McNinch L. et al. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia // Journal of Clinical Oncology.- 1996.- Vol. 14.- P. 2370−2376.
- Jackson J.F., Boyett J., Pullen J. et al. Favorable prognosis associated with hyperdiploidy in children with acute lymphocytic leukemia correlates with extra chromosome 6 // Cancer.- 1990.- Vol. 66.- P. 1184−1189.
- J. Bernard, M. Baron, M. Weil et al. Etude de la remission complete des leucemies aigues //Nouv. Rev. Fr. Hematol.- 1962.- N 2.- P. 195−222.
- Johansson B., Moorman A.V., Haas O.A. et al. Hematologic malignancis with t (4-llXq21−23) a cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases // Leukemia.- 1998.- Vol. 12.- P. 779−787.
- Jones B., Freeman A.I., Shuster J.J. et al. Lower incidence of meningeal leukemia when prednisone replaced by dexametasone in the treatment of acute lymphocytic leukemia // Medical Pediatric Oncology.- 1991.- Vol. 19.- P. 269 275.
- Jones B., Holland J.F., Glidewell O. et al. Optimal use of 1-asparaginase (NSC-109 229) in acute lymphocytic leukemia // Medical and Pediatric Oncology.- 1977.- Vol. 3.- P. 387−400.
- Jonsson O.G., Kamen B.A. Methotrexate and childhood leukemia // Cancer Investigation.- 1991.- Vol. 9.- P. 53−60.
- Joos S., Falk M.H., Lichter P. et al. Variable breakpoints in Burkitt lymphoma cells with chromosomal t (8- 14) translocation separate c-myc and the IgH locus up to several hundred kb // Human Molecular Genetics.- 1992.- Vol. 1.- P. 625 632.
- J. Serrano, J. Roman, A. Jimenez et al. Genetic, phenotypic and clinical features of acute lymphoblastic leukemias expressing myeloperoxidase mRNA detected by RT-PCR // Leukemia.- 1999.- Vol. 13.- P. 175−180.
- Kelly A. Look, Michael D. Amy Ion. Therapy of acute lymphoblastic leukemia of T-cell phenotype // International Journal of Pediatric Hematology/Oncology.- 1998.- Vol. 5.- P. 73−80.
- Kishimoto T., Goyert S., Kikutani H. et al. CD antigens 1996 // Blood.-1997.- Vol. 89.- p. 3502.
- Kurtzberg J., Asselin B., Poplack D. et al. Antibodies to asparaginase alter pharmacokinetics and decrease enzyme activity in patients on asparaginase therapy // Proceedings of the American Association for Cancer Research.- 1993.-Vol. 34.- p. 304.
- K.W. Maloney, J.J. Shuster, S. Murphy et al. Long-term results of treatment studies childhood acute lymphoblastic leukaemia: Pediatric Oncology Group studies from 1986−1994 // Leukemia.- 2000.- Vol. 14.- P. 2276−2285.
- L.B. Silverman, L. Declerck, R.D. Gelber et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukaemia (1981−1995) // Leukemia.- 2000.- Vol. 14.- P. 22 472 256.
- Li F.P., Cassidy J.R., Jaffe N. Risk of secondary tumors in survivors of childhood leukemia//Cancer.- 1975.- Vol. 35.- P. 1230−1235.
- Loh M.L., Silverman L.B., Young M.L. et al. Incidence of TEL/AML1 fusion in children with relapsed of acute lymphoblastic leukemia // Blood.-1998.- Vol. 92.- P. 4792−4797.
- Look T. Oncogenic transcription factors in the human acute leukemias // Science.- 1997.- Vol. 278.- P. 1059−1064.
- Maloney K.W., Shuster J.J., Murphy S. et al. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies frome 1986−1994 // Leukemia.- 2000.- Vol. 14.- P. 2276−2285.
- Miller D.R., Krailo M., Bleyer W.A. et al. Prognostic implications of blast cell morphology in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group // Cancer Treat Rep.- 1985.- Vol. 69.- P. 12 111 221.
- Miller D.R., Leikin S., Albo V. et al. Prognostic importance of morphology (FAB classification) in childhood acute lymphoblastic leukaemia (ALL) // British Journal of Haematology.- 1981.- Vol. 48.- P. 199−206.
- Moe P.J., Seip M., Finne P.H. Intermediate dose methotrexate in childhood acute lymphocytic leukemia // European Paediatric Haematology Oncology.-1984.- Vol. 1.- P. 1−6.
- Moe P.J., A. Holen. High dose methotrexate in childhood ALL // Pediatric Hematology and Oncology.- 2000.- Vol. 17.- P. 615−622.
- M. Schrappe, A. Reiter, H. Riehm. Prophilaxis and treatment of neoplastic meningeosis in childhood acute lymphoblastic leukemia // Journal of Neuro-Oncology.- 1998.- Vol. 38.- P. 159−165.
- M. Schrappe, A. Reiter, M. Zimmermann et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM group from 1981 to 1995 // Leukemia.- 2000.- Vol. 14.- P. 2205−2222.
- Niemeyer C.M., Gelber R.D., Tarbell N.J. et al. Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81−01 update)// Blood.- 1991.- Vol. 78.- P. 2514−2519.
- Nowak-Gottl U., Werber G., Ziemann D. Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL // Haematologica.- 1996.- Vol. 81.- P. 127−131.
- Otten J., Suciu S., Lutz P. et al. The importance of L-asparaginase (A'ase) in the treatment of acute lymphoblastic leukemia (ALL) in children // Blood.-19%.- Vol. 88 (Suppl. 1) (Abstr. 2633).
- Parker S.L., Tong T., Bolden S., Wingo P. Cancer statistics // Cancer Journal of Clinic.- 1997.- Vol. 47.- P. 5−27.
- Pearson A.D.J., Mills S., Amineddine H.A. et al. Pharmacokinetics of oral and intramuscular methotrexate in children with acute lymphoblastic leukemia // Cancer Chemotherapy and Pharmacology.- 1987.- Vol. 20.- P. 243−247.
- P.G. Moe, H. Seidel, F. Wesenberg et al. High-dose methotrexate (4−8 g/m/24hr) in childhood acute lymphocytic leukemia // International Journal of Pediatric Hematology/Oncology.- 1998.- Vol. 5.- P. 155−162.
- Pieters R., den Boer M.L., Durian M. et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia: implications for reatment of infants // Leukemia.-1998.-Vol. 12.- P. 1344−1348.
- Practical application of of minimal residual disease assessment in childhood acute lymphoblastic leukemia (Annotation) // British Journal of Haemotology.-2001.-Vol. 112.- P. 275−281.
- Privitera E., Kamps M.P., Hayashi Y. et al. Diferent molecular consequences of the 1−19 chromosomal translocation in childhood B-cell precursor acute lymphoblastic leukemia // Blood.- 1992.- Vol. 79.- P. 1781−1788.
- Pui C.H. Acute leukemias with the t (4-l I)(q21-q23) // Leukemia and Lymphoma.- 1992.- Vol. 7.- P. 173−179.
- P. S. Gaynon, B.C. Bostrom, G.H. Reaman et al. Childrens Cancer Group initiatives in childhood acute lymphoblastic leukemia // International Journal of Pediatric Hematology/Oncology.- 1998.- Vol. 5.- P. 99−114.
- P. S. Gaynon, M.E. Trigg, N.A. Heerema et al. Childrens Cancer Group Trials in childhood acute lymphoblastic leukaemia: 1983−1995 // Leukemia.- 2000.-Vol. 14.- P. 2223−2233.
- Pui C.H. Acute lymphoblastic leukemia // Pediatr Clinical of North America.-1997.- Vol.44.- P. 831−846.
- Pui C.H. Childhood leukemias // The New England Journal of Medcicine.-1995.- Vol. 332.- N 24.- P. 1618−1629.
- Pui C.H., Behm F.G., Crist W.M. Clinical and biologic relevance of immunologic marker studiesin childhood acute lymphoblastic leukaemia II Blood.- 1993.- Vol. 82.- P. 343−362.
- Pui C.H., Boyett J.M., Relling M.V. et al. Sex differences in prognosis for children with acute lymphoblastic leukaemia // Journal of Clinical Oncology.-1999.- Vol. 17.- P. 818−824.
- Pui C.H., Crist W.M. Biology and treatment of acute lymphoblastic leukemia //Journaj of Pediatric.- 1994.- Vol. 124.- P. 491−503.
- Pui C.H., Frankel L.S., Carroll J. et al. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t (4-l lXq21-q23): a collaborative study of 40 cases // Blood.- 1991.- Vol. 77.- P. 440−447.
- Pui C.H., Kane J.R., Crist W.M. Biology and treatment of infant leukemias. // Leukemia.- 1995.- Vol. 9, — P. 762−769.
- Pui C.H., Mahmoud H.H., Rivera G.K. et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia // Blood.- 1998.- Vol. 92.- P. 411 415.
- Pui C.H., Raimondi S.C. General Report on the European Union Concerted Action Workshop on 1 lq23 // Leukemia.- 1998.- Vol. 12.- P. 776−778.
- Pui C.H., Raimondi S.C., Head D.R. et al. Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse // Blood.-1991.- Vol. 78.- P. 1327−1337.
- Pullen J., Shuster J.J., Link M. Et al. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia
- ALL), as compared to those with B-precursor ALL // Leukemia.- 1999.- Vol. 13.- P. 1696−1707.
- Raynaud S.D., Dastugue N., Zoccola D. et al. Cytogenetic abnormalities associated with the t (12−21): a collaborative study of 169 children with t (12−21)-positive acute lymphoblastic leukemia // Leukemia.- 1999.- Vol. 13.- P. 13 251 330.
- R.C. Ribeiro, C.H. Pui. Characterization and managment of poor-prognosis childhood acute lymphoblastic leukemia // International Journal of Pediatric Hematology/Oncology.- 1998.- Vol. 5.- P. 89−98.
- Reaman G., Zeltzer P., Bleyer A. et al. Acute lymphoblastic leukemia in infants less than one year of age: a cumulative experience of the Children’s Cancer Study Group // Journal of Clinical Oncology.- 1985.-Vol. 3.- P. 15 131 521.
- Reiter AM Schrappe M., Ludwig W.D. et al. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group // Blood.- 1992.- Vol. 80.- P. 2471−2478.
- Reiter A., Schrappe M., Ludwig W.D. et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: results and conclusions of the multicenter trial ALL-BFM 86 // Blood.- 1994.- Vol. 84.- P. 3122−3133.
- R. Gorlick, E. Goken, T. Trippet et al. Intrinsic and acquired resistance to methotrexate in acute leukemia // New England Journal of medicine.- 1996.- Vol. 335.-№ 14.- P.1041−1048.
- Ribeiro R.C., Broniscer A., Rivera G.K. et al. Philadelphia chromosome-positive acute lymphocytic leukemia in children: durable responses to chemotherapy associated with low initial white blood cell counts // Leukemia.-1997.-Vol. 11.-P. 1493−1496.
- Riehm H., Gadner H., Henze G. et al. The Berlin childhood acute lymphoblastic leukemia therapy study, 1970−1976 // American Journal of Pediatric Hematology Oncology.- 1980.- Vol. 2.- P. 299−306.
- Riehm H., Reiter A., Schrappe M. et al. Corticosteroid-dependent reduction of leucocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood // Klinische Pediatrics.- 1987.- Vol. 199.- P. 151−160.
- Rivera G.K., Raimondi S.C., Hancock M.L. et al. Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy // Lancet.- 1991.- Vol. 337.- P. 61−66.
- R. Maners, I. Ramirez, J. Mullins, D. Pinkel. Pilot studies of species-specific chemotherapy of childhood acute lymphoblastic leukemia using genotype and immunophenotype // Leukemia.- 2000.- Vol. 14.- P. 1354−1361.
- Romana S.P., Le Coniat M., Berger R. t (12−21): a new recurrent translocation in acute lymphoblastic leukemia // Genes, Chromosomes and Cancer.- 1994,-Vol. 9.- P. 186−191.
- Romana S.P., Poirel H., Leconiat M. et al. High frequency of t (12−21) in childhood B-lineage acute lymphoblastic leukemia // Blood.- 1995.- Vol. 86.- P. 4263−4269.
- Rubnitz J.E., Downing J.R., Pui C-H, et al. TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance // Journal Clinical Oncology.- 1997.- Vol. 15.- P. 1150−1157.
- Rubnitz J.E., Link M.P., Shuster J.J. et al. Frequency and prognostic sigificance of HRX rearrangements in infant ute lymphoblastic leukemia: a Pediatric Oncology Group study // Blood/-1994.- Vol. 84.- P. 570−573.
- Rubnitz J.E., Pui C.H., Downing J.R. The role of TEL fusion genes in pediatric leukemias // Leukemia.-1999.- Vol. 13.- P. 6−13.
- Schlieben S., Borkhardt A., Reinisch I. et al. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL) // Leukemia.- 1996.- Vol. 10.- P. 957−963.
- Schrappe M., Arico M., Harbott J. et al. Ph+ childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome // Blood.- 1998.- Vol. 92.- P. 2730−2741.
- Schrappe M., Reiter A., Ludwig W.D. et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial irradiation: results of trial ALL-BFM 90 // Blood.- 2000.- Vol. 95.- P. 33 103 322.
- Seeker-Walker L.M. Chromosomes and Genes in Acute Lymphoblastic Leukaemia // New York: Chapman & Hall, 1997.
- Seeker-Walker L.M., Berger R., Fenaux P. et al. Prognostic significance of the balanced t (l-19) and unbalanced der (19)t (l-19) translocations in acute lymphoblastic leukemia // Leukemia.- 1992.- Vol. 6.- P. 363−369.
- Schrappe M., Reiter A., Riehm H. Prophylaxis and treatment meningeosis in childhood acute lymphoblastic leukemia // Journal of Neuro-Oncology.- 1998.-Vol. 38.- P. 159−165.
- Silverman L.B., McLean T.W., Gelber R.D. et al. Intensified therapy for infants with acute lymphoblastic leukemia (ALL): results from the Dana-Farber Cancer Institute Consortium // Cancer.- 1997.- Vol. 80.- P. 2285−2295.
- Soussai C., Patte C., Ostro M. et al. Small o cleaved cell lymphoma and leukemia in adults: a retrospective study of 65 adults treated with the LMB pediatric protocols // Blood.- 1995.- Vol. 85.- P. 664−74.
- S. Yokota, T. Seriu, M. Nakao et al. Clinical implication of minimal residual disease in childhood acute lymphoblastic leukemia // International Journal of Pediatric Hematology/Oncology.- 1998.- Vol. 5.- P. 231−249.
- Uckan F.M., Sather H.N., Gaynon P. S. et al. Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the CCG // Blood.- 1997.- Vol. 90.- P. 28−35.
- V. Conter, M. Arico, M.G. Valsecchi et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Acute Lymphoblastic Leukaemia Studies, 1982−1995 // Leukemia.- 2000.- Vol. 14.- P. 2196−2204.
- Verhagen O.J.H.M., Willemse M.J., Breunis W.B. et al. Application of germline IGH probes in real-time quantitative PCR for the detection of minimalresidual disease in acute lymphoblastic leukemia // Leukemia.- 2000.- Vol. 14.-P.1426−1435.
- Vieira Pinheiro J.P., Ahlke E., Nowak-Gottl U. et al. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols // British Journal of Haematology.- 1999.- Vol. 104.- P. 313−320.
- W.A. Ramps, A.J.P. Veerman, E.R. van Weerden et al. Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukaemia, 1984−1991 // Leukemia.- 2000.- Vol. 14.- P. 2240−2246.
- Wang J.J., Freeman A.I., Sinks L.F. Treatment of acute lymphocytic leukemia by high-dose intravenous methotrexate // Cancer Results.- 1976.- Vol. 36.- P. 1441−1444.
- ОЛЛ острый лимфобластный лейкоз
- ОРВИ острая респираторная вирусная инфекция ППР — полная продолжительная ремиссия СИФ — средняя интенсивность флюоресценции
- BFM (Берл и н -Фран кфурт- М юн стер) — аббревиатура названия кооперативной группы
- CCG аббревиатура названия кооперативной группы — Children’s Cancer Group1. HRG группа высокого риска
- EFS бессобытийная выживаемость
- DCLSG аббревиатура названия кооперативной группы — Dutch Childhood Leukemia Group
- DFCI аббревиатура названия кооперативной группы — Dana-Farber Cancer Institute
- MRD минимальная резидуальная болезнь MRG — группа среднего риска NCI — национальный институт рака (США) OS — общая выживаемость
- POG аббревиатура названия кооперативной группы — Pediatric Oncology Group RFS — безрецидивная выживаемость
- RT-PCR метод обратной транскрипции полимеразной цепной реакции SRG — группа стандатного риска